Syndax Pharmaceuticals, Inc. Increase (Decrease) in Inventories
Syndax Pharmaceuticals, Inc. (SNDX) reported Increase (Decrease) in Inventories of $220.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$1.84M, a 114.25% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $2.06M, a 50.85% decline year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $7.80M, a 2031.42% increase year-over-year.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was $7.18M.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2025 was $32.09M, a 8668.03% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2024 was $366.00K.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2023 was $0.00.
- Syndax Pharmaceuticals, Inc. increase (decrease) in inventories for fiscal 2022 was $0.00.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $220.00K 10-Q · filed 2026-08-04 | $8.02M derived: sum of 3 quarters · filed 2026-08-04 | $15.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.06M 10-Q · filed 2026-04-30 | $9.86M derived: sum of 2 quarters · filed 2026-04-30 | $17.04M derived: sum of 3 quarters · filed 2026-04-30 | $29.96M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.98M derived: sum of 2 quarters · filed 2026-02-26 | $27.90M derived: sum of 3 quarters · filed 2026-08-04 | $32.09M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $20.10M derived: sum of 2 quarters · filed 2026-08-04 | $24.29M 10-Q · filed 2025-11-03 | $24.66M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $12.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $17.11M 10-Q · filed 2026-08-04 | $17.47M derived: sum of 3 quarters · filed 2026-08-04 | $17.47M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.19M 10-Q · filed 2026-04-30 | $4.56M derived: sum of 2 quarters · filed 2026-04-30 | $4.56M derived: sum of 3 quarters · filed 2026-04-30 | $4.56M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $366.00K derived: sum of 2 quarters · filed 2026-02-26 | $366.00K derived: sum of 3 quarters · filed 2026-02-26 | $366.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $0.00 10-Q · filed 2025-08-04 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |